8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 17, 2026·SEC
Material company update
Apr 9, 2026·SEC
Theriva Biologics, Inc.(TOVX)Earnings, Financials & Key Ratios
TOVX•AMEX
$0.36
$13M mkt cap·Price updated May 7, 2026
AboutTheriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company was formerly known as Synthetic Biologics, Inc. and changed its name to Theriva Biologics Inc. in October 2022. Theriva Biologics Inc. is headquartered in Rockville, Maryland.Show more
- Revenue$0
- EBITDA-$15M+43.1%
- Net Income-$25M+1.6%
- EPS (Diluted)-2.08+89.1%
- ROE-146.58%-67.9%
- ROIC-161.17%-13.0%
- Debt/Equity0.17+108.2%
TOVX Key Insights
Theriva Biologics, Inc. (TOVX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 91 (top 9%)
- ✓Trading at only 0.3x book value
✗Weaknesses
- ✗Profits declining 20.2% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
TOVX Price & Volume
Theriva Biologics, Inc. (TOVX) stock price & volume — 10-year historical chart
Loading chart...
TOVX Growth Metrics
Theriva Biologics, Inc. (TOVX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM7.43%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM87.77%
Return on Capital
10 Years-141%
5 Years-46.58%
3 Years-53.53%
Last Year-53.65%
TOVX Recent Earnings
Theriva Biologics, Inc. (TOVX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)
Q2 2026Latest
May 5, 2026EPS
$0.05
Est $0.05
+0.0%
Revenue
$300,000
Q2 2026
Mar 12, 2026EPS
$1.85
Est $0.43
+525.3%
Revenue
—
Q4 2025
Nov 12, 2025EPS
$0.45
Est $0.38
-18.4%
Revenue
—
Q3 2025
Aug 11, 2025EPS
$1.93
Est $0.38
-407.9%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.05vs $0.05+0.0% | $300,000 |
| Q2 2026 | Mar 12, 2026 | $1.85vs $0.43+525.3% | — |
| Q4 2025 | Nov 12, 2025 | $0.45vs $0.38-18.4% | — |
| Q3 2025 | Aug 11, 2025 | $1.93vs $0.38-407.9% | — |
Based on last 12 quarters of dataView full earnings history →
TOVX Peer Comparison
Theriva Biologics, Inc. (TOVX) competitors in Microbiome and Phage Therapeutics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NKTR | 1.69B | 83.37 | -8.57 | -43.89% | -297.07% | -399.1% | 1.66 | |
 IMVT | 5.53B | 27.22 | -9.97 | -47.07% | 0.00 | |||
 CRVS | 1.23B | 14.59 | -27.53 | -38.92% | 0.02 | |||
 AGEN | 132.45M | 3.75 | -1102.94 | 10.37% | 0.1% | |||
 IMMP | 63.65M | 0.43 | -1.42 | 31.28% | -11.72% | -72.51% | 0.01 | |
 TPVG | 242.54M | 5.99 | 4.91 | 36.55% | -3.39% | 1.33 | ||
 VVOS | 5.49M | 0.66 | -0.30 | 8.91% | -98.77% | -6.76% | 0.19 | |
 SNDX | 1.81B | 20.54 | -6.24 | 6.28% | -112.01% | -256.66% | 5.36 |
Compare TOVX vs Peers
Theriva Biologics, Inc. (TOVX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TOVX Income Statement
Theriva Biologics, Inc. (TOVX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 245K | 272K | 0 | 0 | 0 | 0 | 0 | 0 | 108K | 27K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -245K▲ 0% | -272K▼ 11.0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -108K▲ 0% | -27K▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | -56.05% | -11.02% | 100% | - | - | - | - | - | - | - |
| Operating Expenses | 26.25M | 17.57M | 15.66M | 10.16M | 14.27M | 21.58M | 21.43M | 26.35M | 14.91M | 22.81M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 7.47M | 5.73M | 4.58M | 5.03M | 6.47M | 7.57M | 7.78M | 7.4M | 15.45M | 16.07M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 18.78M | 11.84M | 11.08M | 5.13M | 7.8M | 11.72M | 14.31M | 12.03M | 8.6M | 5.99M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 2.29M | -660K | 6.92M | -9.14M | 749K |
| Operating Income | -26.25M▲ 0% | -17.57M▲ 33.1% | -15.66M▲ 10.9% | -10.16M▲ 35.1% | -14.27M▼ 40.5% | -21.58M▼ 51.2% | -21.43M▲ 0.7% | -26.35M▼ 22.9% | -15.02M▲ 43.0% | -12.73M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | 33.12% | 33.07% | 10.86% | 35.13% | -40.49% | -51.19% | 0.7% | -22.93% | 42.99% | - |
| EBITDA | -26.01M | -17.3M | -15.42M | -9.96M | -14.19M | -21.5M | -21.3M | -26.21M | -14.91M | -12.65M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 33.48% | 33.48% | 10.84% | 35.43% | -42.45% | -51.52% | 0.93% | -23.07% | 43.1% | 49.54% |
| D&A (Non-Cash Add-back) | 245K | 272K | 240K | 201K | 87K | 85K | 135K | 137K | 108K | 82K |
| EBIT | -26.25M | -17.57M | -15.66M | -10.16M | -14.27M | -19.29M | -22.09M | -19.43M | -15.02M | -20.33M |
| Net Interest Income | 0 | 0 | 283K | 44K | 6K | 512K | 1.44M | 697K | 287K | 191K |
| Interest Income | 21K | 67K | 283K | 44K | 6K | 512K | 1.44M | 697K | 287K | 273K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 10.76M | 4.15M | 283K | 44K | 6K | 471K | 1.44M | 693K | -8.72M | -8.73M |
| Pretax Income | -15.49M▲ 0% | -13.42M▲ 13.4% | -15.38M▼ 14.6% | -10.12M▲ 34.2% | -14.27M▼ 41.0% | -21.11M▼ 48.0% | -19.99M▲ 5.3% | -25.65M▼ 28.3% | -23.74M▲ 7.5% | -21.46M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | -1.43M | -1.64M | 0 | 1.51M | 1.51M |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 6.75% | 8.2% | 0% | -6.36% | -7.04% |
| Net Income | -15.17M▲ 0% | -13.37M▲ 11.9% | -15.3M▼ 14.5% | -10.04M▲ 34.4% | -14.27M▼ 42.1% | -19.68M▼ 38.0% | -18.35M▲ 6.8% | -25.65M▼ 39.8% | -25.25M▲ 1.6% | -22.97M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 44.33% | 11.91% | -14.48% | 34.37% | -42.06% | -37.98% | 6.79% | -39.81% | 1.57% | 7.43% |
| Net Income (Continuing) | -15.49M | -13.42M | -15.38M | -10.12M | -14.27M | -19.68M | -18.35M | -25.65M | -25.25M | -22.97M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | -1.91M | -2.91M | -2.88M | -2.77M | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -42.70▲ 0% | -21.45▲ 49.8% | -9.14▲ 57.4% | -6.60▲ 27.8% | -1.90▲ 71.2% | -32.66▼ 1618.9% | -28.48▲ 12.8% | -19.03▲ 33.2% | -2.08▲ 89.1% | -0.56▲ 0% |
| EPS Growth % | 57.79% | 49.77% | 57.39% | 27.79% | 71.21% | -1618.95% | 12.8% | 33.18% | 89.07% | 87.77% |
| EPS (Basic) | -42.70 | -21.45 | -9.14 | -6.60 | -1.90 | -32.66 | -28.49 | -19.03 | -2.08 | - |
| Diluted Shares Outstanding | 355.33K | 623.24K | 1.64M | 1.9M | 12.19M | 613.09K | 644.28K | 1.35M | 12.14M | 41.07M |
| Basic Shares Outstanding | 355.33K | 623.24K | 1.64M | 1.9M | 12.19M | 613.09K | 644K | 1.35M | 12.14M | 41.07M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
TOVX Balance Sheet
Theriva Biologics, Inc. (TOVX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 17.94M | 29.51M | 16.43M | 7.93M | 68.86M | 45.52M | 27.4M | 16.28M | 17.47M | 16.76M |
| Cash & Short-Term Investments | 17.12M | 28.92M | 15.04M | 6.23M | 67.33M | 41.79M | 23.18M | 11.61M | 13.06M | 14.43M |
| Cash Only | 17.12M | 28.92M | 15.04M | 6.23M | 67.33M | 41.79M | 23.18M | 11.61M | 13.06M | 14.43M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 46K | 0 | 3K | 469K | 0 | 231K | 1.94M | 3.32M | 3.83M | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 458K | 0 | 0 | 0 | 576K | 2.33M |
| Total Non-Current Assets | 895K | 630K | 809K | 476K | 1.51M | 26.34M | 27.82M | 19.07M | 20.77M | 21.49M |
| Property, Plant & Equipment | 872K | 607K | 786K | 453K | 1.48M | 1.54M | 2.18M | 1.54M | 1.02M | 2.14M |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 5.53M | 5.7M | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 19.15M | 19.75M | 17.36M | 19.62M | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 99K | 102K | 0 | 46K | 92K |
| Other Non-Current Assets | 23K | 23K | 23K | 23K | 23K | -3.15M | 78K | 171K | 82K | 19.64M |
| Total Assets | 18.84M▲ 0% | 30.14M▲ 60.0% | 17.23M▼ 42.8% | 8.41M▼ 51.2% | 70.36M▲ 736.7% | 71.86M▲ 2.1% | 55.22M▼ 23.2% | 35.35M▼ 36.0% | 38.24M▲ 8.2% | 38.25M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
| Asset Growth % | -16.27% | 60% | -42.82% | -51.2% | 736.68% | 2.13% | -23.16% | -35.98% | 8.17% | -11.5% |
| Total Current Liabilities | 9.79M | 3.38M | 5.28M | 2.97M | 3.55M | 7.06M | 6.74M | 7.58M | 10.01M | 10.26M |
| Accounts Payable | 2.02M | 1.03M | 2.31M | 886K | 524K | 915K | 770K | 859K | 1.01M | 608K |
| Days Payables Outstanding | 3.01K | 1.39K | - | - | - | - | - | - | 3.43K | 10.22K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 57K | 63K | 61K | 606K | 545K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 4.17M | 99K | 0 | 868K | 0 | 4.47M | 906K | 1.8M | 8.39M | 9.11M |
| Current Ratio | 1.83x | 8.72x | 3.11x | 2.67x | 19.37x | 6.45x | 4.07x | 2.15x | 1.74x | 1.74x |
| Quick Ratio | 1.83x | 8.72x | 3.11x | 2.67x | 19.37x | 6.45x | 4.07x | 2.15x | 1.74x | 1.74x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 12.46M | 302K | 473K | 186K | 1.4M | 10.24M | 8.78M | 8.7M | 12.84M | 12.59M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 221K | 162K | 92K | 1.67M | 1.52M |
| Capital Lease Obligations | 0 | 0 | 473K | 186K | 1.4M | 1.19M | 1.44M | 873K | 352K | 1.37M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 1.62M | 0 | 762K | 0 | 430K |
| Other Non-Current Liabilities | 402K | 302K | 0 | 0 | 0 | 7.21M | 7.18M | 6.97M | 10.82M | 43.05M |
| Total Liabilities | 22.25M | 3.69M | 5.75M | 3.15M | 4.96M | 17.3M | 15.52M | 16.29M | 22.86M | 22.85M |
| Total Debt | 0 | 0 | 722K | 473K | 1.53M | 1.68M | 2.15M | 1.56M | 2.63M | 2.07M |
| Net Debt | -17.12M | -28.92M | -14.32M | -5.75M | -65.8M | -40.1M | -21.02M | -10.04M | -10.43M | -12.36M |
| Debt / Equity | - | - | 0.06x | 0.09x | 0.02x | 0.03x | 0.05x | 0.08x | 0.17x | 0.17x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.16x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.98x |
| Interest Coverage | - | - | - | - | - | - | - | - | - | - |
| Total Equity | -3.41M▲ 0% | 26.45M▲ 875.8% | 11.49M▼ 56.6% | 5.26M▼ 54.2% | 65.41M▲ 1144.0% | 54.56M▼ 16.6% | 39.7M▼ 27.2% | 19.07M▼ 52.0% | 15.38M▼ 19.3% | 15.4M▲ 0% |
| Equity Growth % | -251.62% | 875.81% | -56.58% | -54.23% | 1143.97% | -16.58% | -27.25% | -51.97% | -19.32% | -154.18% |
| Book Value per Share | -9.60 | 42.45 | 6.99 | 2.77 | 5.37 | 89.00 | 61.61 | 14.14 | 1.27 | 0.37 |
| Total Shareholders' Equity | -1.5M | 29.36M | 14.37M | 8.03M | 65.41M | 54.56M | 39.7M | 19.07M | 15.38M | 15.4M |
| Common Stock | 129K | 15K | 17K | 29K | 13K | 16K | 18K | 3K | 34K | 45K |
| Retained Earnings | -194.17M | -219.46M | -235.54M | -248.09M | -271.28M | -290.97M | -309.32M | -334.97M | -358.71M | -360.75M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | -288K | -288K | -288K | -288K | 0 |
| Accumulated OCI | -12.05M | 0 | 0 | 0 | 0 | -679K | 32K | -1.18M | 755K | 377K |
| Minority Interest | -1.91M | -2.91M | -2.88M | -2.77M | 0 | 0 | 0 | 0 | 0 | 0 |
TOVX Cash Flow Statement
Theriva Biologics, Inc. (TOVX) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -20.2M | -17.28M | -13.87M | -12.17M | -12.89M | -19.08M | -19M | -16.94M | -16.67M | -16.67M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | 27.59% | 14.48% | 19.71% | 12.29% | -5.93% | -48.04% | 0.45% | 10.84% | 1.58% | 40.05% |
| Net Income | -15.49M | -13.42M | -15.38M | -10.12M | -14.27M | -19.68M | -18.35M | -25.65M | -23.74M | -22.97M |
| Depreciation & Amortization | 245K | 272K | 240K | 201K | 87K | 85K | 135K | 137K | 108K | 106K |
| Stock-Based Compensation | 3.41M | 2.07M | 340K | 350K | 416K | 475K | 552K | 671K | 654K | 288K |
| Deferred Taxes | 0 | -4.08M | 0 | 0 | 0 | -1.43M | -1.64M | -888K | 0 | -409K |
| Other Non-Cash Items | -10.74M | 71K | 72K | 178K | 166K | 2.27M | -2M | 8.07M | 9.37M | 9.87M |
| Working Capital Changes | 2.37M | -2.19M | 855K | -2.78M | 709K | -806K | 2.31M | 726K | -3.06M | -2.77M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 27K | -987K | 1.28M | -1.43M | -363K | -385K | -157K | 123K | 69K | 112K |
| Cash from Investing | -212K | -7K | 0 | -9K | -14K | -4.4M | -202K | -1K | -35K | -35K |
| Capital Expenditures | -212K | -7K | 0 | -9K | -14K | -116K | -202K | -1K | -35K | -35K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | -4.28M | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | -4.28K | 0 | 0 | 0 | 0 |
| Cash from Financing | 18.48M | 29.09M | 0 | 3.36M | 74M | -1.93M | 625K | 5.5M | 18.19M | 18.99M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | -1.38M | -75K | -67K | 1.44M | 92K |
| Equity Issued (Net) | 18.31M | 29.09M | 0 | 3.36M | 65.96M | 2.45M | 2.22M | 5.56M | 13.53M | 13.53M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | -288K | 0 | 0 | 0 | 0 |
| Other Financing | 166K | 0 | 0 | 0 | 8.04M | -3M | -1.52M | 0 | 3.23M | 5.37M |
| Net Change in Cash | -1.94M▲ 0% | 11.8M▲ 708.7% | -13.87M▼ 217.5% | -8.82M▲ 36.4% | 61.1M▲ 792.9% | -25.44M▼ 141.6% | -18.61M▲ 26.9% | -11.57M▲ 37.8% | 1.4M▲ 112.1% | 4.42M▲ 0% |
| Free Cash Flow | -20.42M▲ 0% | -17.29M▲ 15.3% | -13.87M▲ 19.7% | -12.18M▲ 12.2% | -12.9M▼ 6.0% | -19.2M▼ 48.8% | -19.2M▲ 0.0% | -16.94M▲ 11.8% | -16.7M▲ 1.4% | -14.4M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | 28.29% | 15.33% | 19.74% | 12.23% | -5.97% | -48.78% | 0% | 11.77% | 1.38% | 14.33% |
| FCF per Share | -57.46 | -27.74 | -8.44 | -6.41 | -1.06 | -31.31 | -29.80 | -12.56 | -1.38 | -1.38 |
| FCF Conversion (FCF/Net Income) | 1.33x | 1.29x | 0.91x | 1.21x | 0.90x | 0.97x | 1.04x | 0.66x | 0.66x | 0.63x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TOVX Key Ratios
Theriva Biologics, Inc. (TOVX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -116.01% | -80.67% | -119.95% | -40.38% | -32.82% | -38.93% | -87.31% | -146.58% | -190.84% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | -230.09% | -97.02% | -142.68% | -161.17% | -161.17% |
| Debt / Equity | - | - | 0.06x | 0.09x | 0.02x | 0.03x | 0.05x | 0.08x | 0.17x | 0.17x |
| FCF Conversion | 1.33x | 1.29x | 0.91x | 1.21x | 0.90x | 0.97x | 1.04x | 0.66x | 0.66x | 0.63x |
TOVX SEC Filings & Documents
Theriva Biologics, Inc. (TOVX) SEC filings — annual & quarterly reports (10-K, 10-Q)
TOVX Frequently Asked Questions
Theriva Biologics, Inc. (TOVX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Theriva Biologics, Inc. (TOVX) grew revenue by 0.0% over the past year. Growth has been modest.
Theriva Biologics, Inc. (TOVX) reported a net loss of $23.0M for fiscal year 2025.
Dividend & Returns
Theriva Biologics, Inc. (TOVX) has a return on equity (ROE) of -146.6%. Negative ROE indicates the company is unprofitable.
Theriva Biologics, Inc. (TOVX) had negative free cash flow of $14.4M in fiscal year 2025, likely due to heavy capital investments.
Explore More TOVX
Theriva Biologics, Inc. (TOVX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates